Header graphic for print
LimeGreenIP News

Tag Archives: paediatric SPC extension

Italian time-machine : Limitation of the duration of an SPC may be decided by the Italian Patent Office

The Board of Appeal of the Italian Patent Office (Commissione dei Ricorsi), by decision published on June 26, 2017, acknowledged the right of the patent holder to ask the Italian Patent Office for the limitation of the duration of a supplementary protection certificate (SPC) further to its recalculation on account of an earlier marketing authorisation. Background

Italy: Teva vs. Novartis – Paediatric extensions of SPCs valid following removal of orphan designation

By order issued on February 26th, 2016 and only recently made available in a public database, the Court of Milan declared the validity of the paediatric extension granted by the Italian Patent Office for Novartis’ SPC covering the medicinal product Glivec (imatinib mesilate), applied for after Novartis’ voluntary removal of the product from the EU

New on LimeGreen IP Knowhow: SPCs for pharmaceutical products – a European guide

We’ve added a new topic to Hogan Lovells’ LimeGreen IP: focused on guiding you through the regulatory regime governing Supplementary Protection Certificates  in Europe. SPCs have for many years proved a fertile area for dispute. This is due to a number of factors including: lack of clarity in the governing legislation; the evolution of new types of medicines leading to questions